EMA Authorised: Inhixa (enoxaparin sodium) — Techdow Pharma Netherlands B.V.

View source ↗

Summary

The EMA has authorised Inhixa (enoxaparin sodium) for Venous Thromboembolism, with Techdow Pharma Netherlands B.V. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Inhixa (enoxaparin sodium)

Snippet

Status: Authorised. Therapeutic area: Venous Thromboembolism. MAH: Techdow Pharma Netherlands B.V.. Decision date: 15/07/2026